Allspring Global Investments’s Avita Medical RCEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-49
Closed -$785 2501
2024
Q1
$785 Sell
49
-42
-46% -$680 ﹤0.01% 2245
2023
Q4
$1.25K Sell
91
-6,596
-99% -$75.6K ﹤0.01% 2130
2023
Q3
$97.7K Buy
+6,687
New +$113K ﹤0.01% 2008
2022
Q2
Sell
-11,279
Closed -$95K 2881
2022
Q1
$95K Buy
11,279
+11,275
+281,875% +$104K ﹤0.01% 2758
2021
Q4
$0 Buy
+4
New +$61 ﹤0.01% 2955

Other funds holding RCEL

Allspring Global Investments's RCEL Position: Q2 2024 in Review

Allspring Global Investments sold out of Avita Medical (RCEL) in Q2 2024, closing a stake of 49 shares — an estimated $785 sold.

Allspring Global Investments first reported a position in RCEL in Q4 2021 and held it in 5 quarters. The position peaked at $97.7K in Q3 2023. 68 funds tracked by Wall St. Rank hold RCEL as of Q2 2024.

  • Allspring Global Investments reported no remaining Avita Medical position as of Q2 2024 after selling out during the quarter.
  • Allspring Global Investments sold 49 Avita Medical shares in Q2 2024, an estimated $785.
  • Allspring Global Investments first reported a position in Avita Medical in Q4 2021 and held it in 5 quarters.
  • Allspring Global Investments's Avita Medical position peaked at $97.7K in Q3 2023.
  • 68 funds tracked by Wall St. Rank held Avita Medical as of Q2 2024.

Based on Allspring Global Investments's 13F filing for Q2 2024, filed 26 Jul 2024.